Fed Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® 250 mg
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's terbinafine
hydrochloride tablets to Novartis' Lamisil® tablets following a single, oral 250 mg (1 x 250
mg) dose administered under fed conditions.